



PharMEDium Services – Recall of hydromorphone

- On June 28, 2019, [PharMEDium Services announced](#) a voluntary, consumer-level recall of 45 lots of [hydromorphone](#) syringes because PharMEDium’s electronic customer ordering system stated it is sulfite-free, but the product contains sulfite.
- The recalled 28,140 hydromorphone syringes were distributed nationwide to a total of 6 customers:

Product Description	NDC #	Lot # (expiration date)
0.5 mg/mL HYDROmorphone HCl in 0.9% Sodium Chloride 1 mL in 3 mL BD Syringe	61533-352-78	Various lots and expiration dates (refer to PharMEDium’s announcement)

- Hydromorphone is used for the relief of moderate to severe pain in opioid tolerant patients.
- Serious adverse reactions could occur in patients with a sulfite allergy who are exposed to hydromorphone containing sulfites. The reactions may range from mild wheezing to severe bronchospasm and anaphylaxis.
- To date, PharMEDium Services has not received any adverse event reports related to sulfite reactions or sensitivity.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled fluorouracil injection.
- Pharmacies and healthcare facilities that have the recalled drug product should immediately quarantine and stop dispensing the recalled drug product.
 - PharMEDium Services has notified all six customers by email/phone and has arranged for replacement orders of all recalled products.
- For more information regarding this recall, contact PharMEDium Services by phone at **1-800-523-7749** or by email at **Quality1@pharmedium.com**.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.